Cdh1 gene mutation hereditary diffuse gastric cancer outcomes: Analysis of a large cohort, systematic review of endoscopic surveillance and secondary cancer risk postulation

Abstract

Hereditary diffuse gastric cancer (HDGC) is a rare signet‐ring cell adenocarcinoma (SRCC) linked to CDH1 (E‐cadherin) inactivating germline mutations, and increasingly other gene mutations. Female CDH1 mutation carriers have additional risk of lobular breast cancer. Risk management includes prophylactic total gastrectomy (PTG). The utility of endoscopic surveillance is unclear, as early disease lacks macroscopic lesions. The current systematic biopsy protocols have unknown efficacy, and other secondary cancer risks are postulated. We conducted a retrospective study of consecutive asymptomatic HDGC patients undergoing PTG, detailing endoscopic, pathologic, and outcome results. A systematic review compared endoscopic biopsy foci detection via random sampling versus Cambridge Protocol against PTG findings. A population‐level secondary-cancer‐risk postulation among sporadic gastric SRCC patients was completed using the Surveil-lance, Epidemiology, and End Results database. Of 97 patients, 67 underwent PTG, with 25% having foci detection on random endoscopic biopsy despite 75% having foci on final pathology. There was no improvement in the endoscopic detection rate by Cambridge Protocol. The postulated hazard ratio among sporadic gastric SRCC patients for a secondary colorectal SRCC was three‐fold higher, relative to conventional adenocarcinoma patients. Overall, HDGC patients should not rely on endoscopic surveillance to delay PTG, and may have secondary SRCC risks. A definitive determina-tion of actual risk requires collaborative patient outcome data banking.